Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
NCT04339751 · National Institute of Neurological Disorders and Stroke (NINDS) · PHASE2 · withdrawn · last registry update 2025-04-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment.” | – | Registry record, National Institute of Neurological Disorders and Stroke (NINDS) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-10Results posted on the registry: University of Miami, Belinostat + Zidovudine (NCT02737046)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Belinostat + Pevonedistat (NCT03772925)
- 2026-03-03Also stopped (terminated): National Cancer Institute (NCI), Belinostat + Pevonedistat (NCT03772925)
- 2026-03-02Results posted on the registry: Antonio Fojo, Entinostat (NCT03211988)
- 2026-03-02Also stopped (terminated): Antonio Fojo, Entinostat (NCT03211988)
- 2026-01-30Also stopped (terminated): National Cancer Institute (NCI), Adavosertib + Belinostat (NCT02381548)
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody + Bevacizumab (NCT03280563)
- 2025-10-16Results posted on the registry: Therapeutic Advances in Childhood Leukemia Consortium, Decitabine + Vorinostat (NCT03263936)
- 2025-10-07Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Pembrolizumab + Entinostat (NCT03978624)
- 2025-10-06Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Pembrolizumab + Vorinostat (NCT03426891)
- 2025-09-16Results posted on the registry: National Cancer Institute (NCI), Belinostat + Decitabine and Cedazuridine (NCT04340843)
- 2025-09-11Also stopped (withdrawn): Judit Pich, a drug against HDAC1 (NCT03619278)
- 2025-06-12Results posted on the registry: National Cancer Institute (NCI), Romidepsin + Lenalidomide (NCT04447027)
- 2025-06-08Results posted on the registry: Columbia University, Panobinostat 15 MG (NCT04804709)
- 2025-06-08Also stopped (terminated): Columbia University, Panobinostat 15 MG (NCT04804709)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-05-16Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Romidepsin + Abraxane (NCT01938833)
- 2025-05-04Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Vorinostat + Pembrolizumab (NCT02638090)
- 2025-05-02Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Panobinostat (NCT01324635)
- 2025-04-16Results posted on the registry: New Approaches to Neuroblastoma Therapy Consortium, Dinutuximab + Vorinostat (NCT03332667)
- 2025-04-04Also stopped (withdrawn): Case Comprehensive Cancer Center, Cisplatin + Vorinostat (NCT05608369)
- 2025-03-20Results posted on the registry: Roberto Pili, Atezolizumab + Bevacizumab (NCT03024437)
- 2025-03-20Also stopped (terminated): Roberto Pili, Atezolizumab + Bevacizumab (NCT03024437)
- 2025-03-20Results posted on the registry: Syndax Pharmaceuticals, entinostat + pembrolizumab (NCT02437136)
- 2025-03-18Results posted on the registry: M.D. Anderson Cancer Center, Busulfan + Gemcitabine Hydrochloride (NCT02506959)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision